VWD Medicine Now Indicated for Prophy

The U.S. FDA approved Takeda’s supplemental Biologics License Application (sBLA) for Von Vendi, to expand its indication for routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD.

Source: LA Kelley Communications, Inc., Communique, October 2025